Research ArticleCancer

PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL+ human leukemia

See allHide authors and affiliations

Science Translational Medicine  07 Feb 2018:
Vol. 10, Issue 427, eaan8735
DOI: 10.1126/scitranslmed.aan8735

Article Information

vol. 10 no. 427

PubMed: 
Print ISSN: 
Online ISSN: 
History: 
  • Received for publication May 31, 2017
  • Accepted for publication October 31, 2017

Author Information

  1. Damian Lai1,2,*,
  2. Min Chen1,*,
  3. Jiechuang Su1,3,
  4. Xiaohu Liu1,2,
  5. Katharina Rothe1,3,
  6. Kaiji Hu1,
  7. Donna L. Forrest2,4,
  8. Connie J. Eaves1,2,3,
  9. Gregg B. Morin3,5 and
  10. Xiaoyan Jiang1,2,3,
  1. 1Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, British Columbia V5Z 1L3, Canada.
  2. 2Department of Medicine, University of British Columbia, Vancouver, British Columbia V5Z 1M9, Canada.
  3. 3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia V6H 3N1, Canada.
  4. 4Leukemia/Bone Marrow Transplant Program of British Columbia, Vancouver, British Columbia V5Z 1M9, Canada.
  5. 5Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, British Columbia V5Z 1L3, Canada.
  1. Corresponding author. Email: xjiang{at}bccrc.ca
    • * These authors contributed equally to this work.

    Altmetric

    Article usage

    Article usage: February 2018 to August 2018

    AbstractFullPdf
    Feb 20184256191368
    Mar 20184633979
    Apr 20183763767
    May 20182552252
    Jun 20182122139
    Jul 20181752626
    Aug 2018332317